We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.31 | 0.48% | 65.51 | 65.43 | 65.89 | 65.8892 | 64.97 | 65.32 | 7,232,521 | 00:55:07 |
From May 2019 to May 2024
By Michael Dabaie
Gilead Sciences Inc. unveiled results from a Phase 1b trial evaluating its vesatolimod as part of a human immunodeficiency virus cure research program.
These findings mark the first clinical data showing toll-like receptor 7 stimulation by vesatolimod is associated with a modestly increased time to viral rebound compared to placebo, as well as enhanced immune function and decreased levels of intact HIV DNA, Gilead said.
"The effects are modest, and no one came close to any definition of a cure, but the data suggests real progress might be made when the drug is used in combination with other approaches," said principal investigator Steven Deeks, professor of medicine at the University of California, San Francisco.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
March 10, 2020 15:22 ET (19:22 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
